Antimetastatic effect of nobiletin through the down-regulation of CXC chemokine receptor type 4 and matrix metallopeptidase-9

Baek, Seung Ho; Kim, Sung-Moo; Nam, Dongwoo; lee, jun-hee; Ahn, Kyoo Seok; Choi, Su-Mi; Kim, Sung Hoon; Shim, Bum Sang; Chang, Ikwhang; Ahn, Kwang Seok

doi:10.3109/13880209.2012.664151

Cited by 35 publications

(23 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we found that nobiletin at low concentrations (up to 100 μM) without cytotoxicity dose-dependently reduced the cell motility, invasion and migration of U2OS and HOS cells. Similarly, such effect has been reported that nobiletin markedly reduces the migration ability of breast cancer cells under noncytotoxic concentrations [26]. In general, nobiletin is considered as a flavonoid with weak cytostatic properties (up to 100 μM) towards progression of cancer cells in vivo and in vitro [22, 24, 27].…”

Section: Discussionmentioning

confidence: 92%

Nobiletin inhibits human osteosarcoma cells metastasis by blocking ERK and JNK-mediated MMPs expression

et al. 2016

View full text Add to dashboard Cite

Nobiletin, a polymethoxyflavone, has a few pharmacological activities, including anti-inflammation and anti-cancer effects. However, its effect on human osteosarcoma progression remains uninvestigated. Therefore, we examined the effectiveness of nobiletin against cellular metastasis of human osteosarcoma and the underlying mechanisms. Nobiletin, up to 100 μM without cytotoxicity, significantly decreased motility, migration and invasion as well as enzymatic activities, protein levels and mRNA expressions of matrix metalloproteinase (MMP)-2 and MMP-9 in U2OS and HOS cells. In addition to inhibition of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK), the inhibitory effect of nobiletin on the DNAbinding activity of the transcription factor nuclear factor-kappa B (NF-κB), cAMP response element-binding protein (CREB), and specificity protein 1 (SP-1) in U2OS and HOS cells. Co-treatment with ERK and JNK inhibitors and nobiletin further reduced U2OS cells migration and invasion. These results indicated that nobiletin inhibits human osteosarcoma U2OS and HOS cells motility, migration and invasion by downregulating MMP-2 and MMP-9 expressions via ERK and JNK pathways and through the inactivation of downstream NF-κB, CREB, and SP-1. Nobiletin has the potential to serve as an anti-metastatic agent for treating osteosarcoma.

show abstract

Section: Discussionmentioning

confidence: 92%

Nobiletin inhibits human osteosarcoma cells metastasis by blocking ERK and JNK-mediated MMPs expression

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Daily consumption of flavonoids has also been reported to reduce the risk of chronic diseases, including cardiovascular diseases and cancer. In particular, polymethoxyflavone, which is a component of citrus fruits (10), has been reported to reduce inflammation (11) and have an antiproliferative effect on human cancer cells (12).…”

Section: Introductionmentioning

confidence: 99%

Effect of natural flavonoids, stilbenes and caffeic acid oligomers on protein glycation

2014

View full text Add to dashboard Cite

Abstract. The aim of the present study was to identify the inhibitory activity of natural flavonoids, stilbenes and caffeic acid oligomers on protein glycation. Antioxidant activity was evaluated using 1,1-diphenyl-2-picrylhydrazyl radical-scavenging activity. The production of 3-deoxyglucosone (3-DG) and advanced glycation end products (AGEs) by glycation reactions were determined by high-performance liquid chromatography and fluorescence, respectively. Certain flavonoids, stilbenes and caffeic acid oligomers prevented AGE production and the IC 50 values of the compounds were compared. These examined compounds are assumed to suppress AGE generation by inhibiting the increase in 3-DG production through a specific unknown mechanism in the early phase of the Maillard reaction, by inhibiting the generation of active oxygen in the later phase and by suppressing the progression of the reaction. Regular, daily consumption of these compounds in the form of a food or extract is expected to aid in the prevention or inhibition of non-enzymatic amino acid glycation in the living body, which is possibly associated with aging, diabetic complications, arteriosclerotic diseases and Alzheimer's disease, and they may also be effective agents in cosmetics promoting anti-aging.

show abstract

“…This inhibition leads to the suppression of the constitutive NF- κ B and MAPKs activation, thus reducing the metastatic potential of breast cancer cells [100]. …”

Section: Role Of Elr+ CXC Chemokine and Cxcl12/sdf-1 α In Promotinmentioning

confidence: 99%

CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors

Santoni

Bracarda

Nabissi

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Chemokines are a superfamily of structurally homologous heparin-binding proteins that includes potent inducers and inhibitors of angiogenesis. The imbalance between angiogenic and angiostatic chemokine activities can lead to abnormalities, such as chronic inflammation, dysplastic transformation, and even tumor development and spreading. In this review, we summarize the current literature regarding the role of chemokines as modulators of tumor angiogenesis and their potential role as therapeutic targets in patients with nonhaematological tumors.

show abstract

Antimetastatic effect of nobiletin through the down-regulation of CXC chemokine receptor type 4 and matrix metallopeptidase-9

Cited by 35 publications

References 58 publications

Nobiletin inhibits human osteosarcoma cells metastasis by blocking ERK and JNK-mediated MMPs expression

Nobiletin inhibits human osteosarcoma cells metastasis by blocking ERK and JNK-mediated MMPs expression

Effect of natural flavonoids, stilbenes and caffeic acid oligomers on protein glycation

CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors

Contact Info

Product

Resources

About